Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by Boomskidon Jan 18, 2023 1:55pm
61 Views
Post# 35231126

RE:RE:RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR

RE:RE:RE:RE:RE:RE:RE:Consequences of a "no" vote: from IRYep, maybe she wouldn't take the chance. But everything she did and didn't do can be discussed in terms of conflict of interest.

It's plausable enough to write a book about it, fiction or nonfiction. Cresence, xB3-001, corporate presentations, the Ellipses leak, all of it can be interpreted either way. I've never seen anything in all of Bioasis's documents that proves or disproves almost any scenario.

jd
<< Previous
Bullboard Posts
Next >>